BOB: Bayesian optimal design for biosimilar trials with co-primary endpoints

DOI10.1002/SIM.9571zbMATH Open1547.62188MaRDI QIDQ6629374FDOQ6629374

Authors Xiaohan Chi, Zhangsheng Yu, Ruitao Lin 

Publication date 29 October 2024

Published in Statistics in Medicine (Search for Journal in Brave)

zbMATH Keywords

powersequential designBayesian optimal designco-primary endpointsbiosimilar

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• A calibrated power prior approach to borrow information from historical data with application to biosimilar clinical trials
• Bayesian design of biosimilars clinical programs involving multiple therapeutic indications
• Bioequivalence trials, intersection-union tests and equivalence confidence sets. With comments and a rejoinder by the authors
• Incorporating historical information in biosimilar trials: challenges and a hybrid Bayesian-frequentist approach
• Practical Bayesian Guidelines for Phase IIB Clinical Trials
• Robust meta‐analytic‐predictive priors in clinical trials with historical control information
• Testing Statistical Hypotheses of Equivalence and Noninferiority

This page was built for publication: BOB: Bayesian optimal design for biosimilar trials with co-primary endpoints

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6629374)